$KOD SEC Filings

Filed On	Filing
26 Oct 2026	Form 4: Yang Taiyin, Director Received 20,000 shares by exercise or conversion ($47K)
23 Oct 2026	Form 4: Borgeson John A., Chief Financial Officer Received 30,000 shares by exercise or conversion ($74.7K) · Sold 30,000 shares ($2.7M)
21 Oct 2026	144
20 Oct 2026	S-3ASR
30 Sep 2026	Form 4: Baker Bros. Advisors Lp, Director and 5 others Bought 681,866 shares ($60.5M) · Bought 33,726 shares ($2.87M)
30 Sep 2026	Form 4: Baker Bros. Advisors Lp, Director and 5 others Bought 418,323 shares ($35M)
30 Sep 2026	Form 4: Baker Bros. Advisors Lp, Director and 5 others Bought 807,840 shares ($58.6M)
30 Sep 2026	SCHEDULE 13D/A
29 Sep 2026	Form 4: Perlroth Victor, Director Received 1,280,524 shares by exercise or conversion ($5.38M)
28 Sep 2026	8-K: Other Events Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-...
14 Aug 2026	SCHEDULE 13G
13 Aug 2026	10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
17 Jul 2026	Form 4: Borgeson John A., Chief Financial Officer Granted 66,500 Stock Option (Right to Buy)
17 Jul 2026	Form 4: Perlroth Victor, Director Granted 100,000 Stock Option (Right to Buy)
02 Jul 2026	Form 4: Yang Taiyin, Director Granted 17,731 Stock Option (Right to Buy)
02 Jul 2026	Form 4: Profusek Robert, Director Granted 17,731 Stock Option (Right to Buy)
02 Jul 2026	Form 4: Levy Richard S, Director Granted 17,731 Stock Option (Right to Buy)
02 Jul 2026	Form 4: Dahiyat Bassil I, Director Granted 17,731 Stock Option (Right to Buy)
02 Jul 2026	Form 4: Bancroft Charles A, Director Granted 17,731 Stock Option (Right to Buy)

Comments